^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Amtagvi (lifileucel)

i
Other names: LN 144, autologous T cell therapy with tumor infiltrating lymphocytes, TIL-ACT, LN-144, LN144
Company:
Iovance Biotherap
Drug class:
Immunostimulant, T lymphocyte replacement
Related drugs:
15d
Enrollment change • Metastases
|
Amtagvi (lifileucel) • LN-145
1m
IOV-END-201: A Study of Lifileucel (tumor-infiltrating Lymphocytes) in Adults with Advanced Endometrial Cancer. (clinicaltrials.gov)
P2, N=60, Recruiting, Iovance Biotherapeutics, Inc. | Not yet recruiting --> Recruiting
Enrollment open
|
cyclophosphamide • Amtagvi (lifileucel)
2ms
Advancements and Challenges in Personalized Therapy for BRAF-Mutant Melanoma: A Comprehensive Review. (PubMed, J Clin Med)
Despite these challenges, tumor-infiltrating lymphocyte (TIL) therapy, as exemplified by lifileucel, has demonstrated notable efficacy against BRAF V600-mutant melanoma. Additionally, early response biomarkers, such as COX-2 and MMP2, along with FDG-PET imaging, offer the potential to improve personalized immunotherapy by predicting patient responses and determining the optimal treatment duration. Future efforts should focus on reducing the T-cell harvesting periods and costs associated with TIL therapy to enhance efficiency and accessibility.
Review • Journal • PD(L)-1 Biomarker • IO biomarker
|
BRAF (B-raf proto-oncogene) • MMP2 (Matrix metallopeptidase 2)
|
BRAF mutation • BRAF V600
|
Amtagvi (lifileucel)
3ms
New P1 trial
|
Amtagvi (lifileucel) • LN-145
4ms
Generation and Characterization of Ex Vivo Expanded Tumor-infiltrating Lymphocytes From Renal Cell Carcinoma Tumors for Adoptive Cell Therapy. (PubMed, J Immunother)
The Gen 2 manufacturing process used for lifileucel successfully expanded functional TILs from RCC samples, enabling further study in a clinical trial. TIME features such as low CD8/FoxP3 ratio and high PD-1 expression within FoxP3 cells warrant study as potential biomarkers of successful TIL expansion.
Preclinical • Journal • Tumor-infiltrating lymphocyte • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • FOXP3 (Forkhead Box P3)
|
Amtagvi (lifileucel)
4ms
New P2 trial • Metastases
|
cyclophosphamide • Amtagvi (lifileucel)
5ms
Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma (clinicaltrials.gov)
P1, N=10, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025
Trial completion date • Trial primary completion date • Metastases
|
Amtagvi (lifileucel)
7ms
IOV-COM-202: Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors (clinicaltrials.gov)
P2, N=178, Recruiting, Iovance Biotherapeutics, Inc. | Trial completion date: Dec 2024 --> Aug 2029 | Trial primary completion date: Dec 2023 --> Aug 2029
Trial completion date • Trial primary completion date
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Amtagvi (lifileucel) • LN-145 • LN-145-S1
8ms
Lifileucel, an Autologous Tumor-infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors. (PubMed, Cancer Discov)
In this phase 2 multicenter study, we evaluated the efficacy and safety of lifileucel (LN-145), an autologous tumor-infiltrating lymphocyte cell therapy, in patients with metastatic non-small cell lung cancer (mNSCLC) who had received prior immunotherapy and progressed on their most recent therapy. Two patients died of treatment-emergent adverse events: cardiac failure and multiple organ failure. Lifileucel is a potential treatment option for patients with mNSCLC refractory to prior therapy.
Clinical • Journal • Checkpoint inhibition • Tumor mutational burden • Tumor-infiltrating lymphocyte • PD(L)-1 Biomarker • IO biomarker • Metastases
|
TMB (Tumor Mutational Burden) • STK11 (Serine/threonine kinase 11)
|
STK11 mutation • PD-L1 negative • TMB-L • PD-L1 negative + TMB-L
|
Amtagvi (lifileucel) • LN-145
8ms
NCI-2021-11063: Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients (clinicaltrials.gov)
P1, N=2, Active, not recruiting, Richard Wu | Recruiting --> Active, not recruiting | N=15 --> 2 | Trial completion date: Dec 2025 --> Dec 2024
Enrollment closed • Enrollment change • Trial completion date • Tumor mutational burden • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • Amtagvi (lifileucel)
8ms
A Study of LN-144 in People With Metastatic Melanoma to the Brain (clinicaltrials.gov)
P1, N=10, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting
Enrollment closed • Metastases
|
Amtagvi (lifileucel)
8ms
Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy. (PubMed, J Immunother Cancer)
Based on the encouraging efficacy, tolerable safety profile, and advancements in a central manufacturing process, lifileucel is now the first US Food and Drug Administration (FDA)-approved TIL cell therapy product...These recommendations provide practical guidelines for optimal clinical management during administration of the TIL cell therapy regimen, and recognition of subsequent management of toxicities. These guidelines are focused on multidisciplinary teams of physicians, nurses, and stakeholders involved in the care of these patients.
Journal • Tumor-infiltrating lymphocyte
|
IL2 (Interleukin 2)
|
Amtagvi (lifileucel)
9ms
Trial primary completion date • Metastases
|
cyclophosphamide • fludarabine IV • Amtagvi (lifileucel) • Imunace (teceleukin)
9ms
A Review of Current and Pipeline Drugs for Treatment of Melanoma. (PubMed, Pharmaceuticals (Basel))
Lifileucel, an FDA-approved tumor-infiltrating lymphocyte therapy, has demonstrated improved response rates in advanced-stage melanoma...While immunotherapy has significantly advanced melanoma treatment, its success varies, prompting research into new drugs and factors influencing outcomes. This review provides insights into current melanoma treatments and recent therapeutic advances.
Review • Journal • PD(L)-1 Biomarker • IO biomarker
|
NRAS (Neuroblastoma RAS viral oncogene homolog) • IL2 (Interleukin 2)
|
BRAF mutation
|
Amtagvi (lifileucel)
11ms
Enrollment open
|
cyclophosphamide • fludarabine IV • Amtagvi (lifileucel) • Imunace (teceleukin)
12ms
New P2 trial
|
cyclophosphamide • fludarabine IV • Amtagvi (lifileucel) • Imunace (teceleukin)
over1year
C-144-01: Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma (clinicaltrials.gov)
P2, N=178, Active, not recruiting, Iovance Biotherapeutics, Inc. | Trial primary completion date: Jul 2021 --> Jan 2025
Trial primary completion date • Metastases
|
BRAF (B-raf proto-oncogene) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
BRAF mutation • BRAF V600
|
Amtagvi (lifileucel)
over1year
A Study of LN-144 in People With Metastatic Melanoma to the Brain (clinicaltrials.gov)
P1, N=10, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Nov 2024 --> Nov 2025
Trial completion date • Trial primary completion date • Metastases
|
Amtagvi (lifileucel)
almost2years
Response to Lifileucel Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy after ICI Resistance Regardless of Definition: An Analysis of the C-144-01 Trial in Patients with Advanced Melanoma (TCT-ASTCT-CIBMTR 2023)
Of 153 pts who received lifileucel, 109 (71%) were primary resistant (SITC definition) and 83 (54%) were primary refractory (study definition). In primary resistant pts, ORR with lifileucel was 33% (95% CI: 24%, 43%) and median DOR was not reached (NR; 95% CI: 12.5 mo, NR). In primary refractory pts, ORR was 31% (95% CI: 22%, 42%) and median DOR was NR (95% CI: 15.1 mo, NR).
Clinical • Tumor mutational burden • Tumor-infiltrating lymphocyte • PD(L)-1 Biomarker • IO biomarker • Metastases
|
TMB (Tumor Mutational Burden) • IFNG (Interferon, gamma) • B2M (Beta-2-microglobulin)
|
IFNG expression
|
Amtagvi (lifileucel)
almost2years
A Study of LN-144 in People With Metastatic Melanoma to the Brain (clinicaltrials.gov)
P1, N=10, Recruiting, Memorial Sloan Kettering Cancer Center
New P1 trial
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600 • BRAF V600K
|
cyclophosphamide • Amtagvi (lifileucel)
2years
Phase classification • Tumor mutational burden • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • Amtagvi (lifileucel)
2years
Number of IL-2 doses and clinical outcomes of tumor-infiltrating lymphocyte (TIL) cell therapy: Post hoc analysis of the C-144-01 trial of lifileucel in patients with advanced melanoma (ESMO-IO 2022)
Background Aldesleukin (IL-2), at high doses in repeat cycles, is approved as monotherapy for patients (pts) with metastatic melanoma...Methods Pts with advanced melanoma received cyclophosphamide and fludarabine (NMA-LD, Day –7 to –1), a single lifileucel infusion (Day 0), and ≤6 IL-2 doses (600,000 IU/kg) every 8–12 h (Day 0–4)...Pts with disease refractory to prior IL-2 monotherapy derived benefit from lifileucel. Presence of G3/4 lymphopenia in all pts at time of IL-2 administration argues against a direct antineoplastic effect of abbreviated IL-2 dosing as part of the lifileucel regimen.
Clinical • Clinical data • Retrospective data • Tumor-Infiltrating Lymphocyte • IO biomarker
|
BRAF (B-raf proto-oncogene) • IL2 (Interleukin 2)
|
BRAF mutation
|
cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • Amtagvi (lifileucel)
over2years
New trial
|
PD-L1 (Programmed death ligand 1)
|
Amtagvi (lifileucel)
over2years
Tumor mutational burden (TMB) in immune checkpoint inhibitor (ICI)-naïve and -experienced patients with metastatic melanoma treated with lifileucel, a tumor-infiltrating lymphocyte (TIL) cell therapy. (ASCO 2022)
Available cases from C1A (ICI-naïve pts receiving lifileucel + pembrolizumab [pembro]) were matched to controls from C2 (pts receiving lifileucel alone after progression on anti?PD-1/PD-L1 therapy); 3 controls per case were matched at least for BRAF status and disease stage at study entry, and if possible, for anatomic site of tumor harvest. Our preliminary data indicate that the efficacy (ORR) of lifileucel may be independent of TMB, regardless of treatment setting, consistent with its proposed immune checkpoint pathway-independent mechanism of action. The percentage of patients with high TMB tended to be lower in tumors with prior ICI exposure than in those that were ICI-naïve.
Clinical • Checkpoint inhibition • Tumor Mutational Burden • Tumor-Infiltrating Lymphocyte • PD(L)-1 Biomarker • IO biomarker
|
BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden)
|
TMB-H
|
Keytruda (pembrolizumab) • Amtagvi (lifileucel)
over2years
Enrollment open
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • Amtagvi (lifileucel)
almost3years
Successful Manufacturing of Tumor-Infiltrating Lymphocyte TIL Cell Therapy from Cryopreserved Melanoma Tumors Shipped from Australia (TCT-ASTCT-CIBMTR 2022)
Background: Lifileucel TIL cell therapy has demonstrated safety and activity in treating patients with advanced melanoma Sarnaik AA, et al... Time to ship fresh tumors from Australia ≥3 days was substantially longer than our experience with tumors shipped within the US <1–2 days, data on file, and logistical challenges may limit the utility of this treatment using fresh tumors . Tumors that were frozen locally in Australia prior to shipment consistently produced sufficient dose for TIL treatment 4/4 samples; TIL manufacturing using fresh tumors was less reliable 3/4 samples. Additional tumor samples will be analyzed to continue optimizing the TIL manufacturing process using samples from Australia.
Tumor-Infiltrating Lymphocyte
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
|
Amtagvi (lifileucel)
almost3years
New P1/2 trial
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • Amtagvi (lifileucel)
over3years
[VIRTUAL] Lifileucel (LN-144), a Cryopreserved Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients with Advanced (Unresectable or Metastatic) Melanoma: Median Duration of Response Not Reached at 28 Month of Study Follow-up (FCI 2021)
Therapy consisted of nonmyeloablative lymphodepletion (cyclophosphamide / fludarabine), a single lifileucel infusion, followed by up to 6 doses of IL-2. post-therapy. Median DOR was still not reached at median follow-up of 28 month of study follow up, and 11 patients (17%) had further SOD reduction since previous data cut of Apr2020. Iovance is investigating lifileucel in earlier disease settings, in combination with ICI, and in other metastatic solid malignancies.
Clinical • Tumor-Infiltrating Lymphocyte • PD(L)-1 Biomarker • IO biomarker
|
BRAF (B-raf proto-oncogene) • IL2 (Interleukin 2)
|
BRAF mutation • BRAF V600
|
fludarabine IV • Amtagvi (lifileucel)
over3years
Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma (clinicaltrials.gov)
P2, N=178, Active, not recruiting, Iovance Biotherapeutics, Inc. | Trial primary completion date: Jul 2020 --> Jul 2021
Clinical • Trial primary completion date
|
BRAF (B-raf proto-oncogene) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
BRAF mutation • BRAF V600
|
Amtagvi (lifileucel)
almost4years
Clinical • Enrollment change • PD(L)-1 Biomarker
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK mutation
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Amtagvi (lifileucel) • LN-145 • LN-145-S1
over4years
[VIRTUAL] Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies. (ASCO 2020)
Lifileucel treatment results in a 36.4% ORR and mDOR was not reached at 17.0 months of median study follow up in a heavily pretreated metastatic melanoma patients with high baseline disease burden who progressed on multiple prior therapies, including anti-PD1 and BRAF/MEK inhibitors, if BRAFv600 mutant. Research Funding: Iovance Biotherapeutics, Inc.
Clinical • Tumor-Infiltrating Lymphocyte • PD(L)-1 Biomarker • IO biomarker
|
IL2 (Interleukin 2)
|
BRAF V600E • BRAF mutation
|
Amtagvi (lifileucel)
almost5years
Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma (clinicaltrials.gov)
P2, N=178, Active, not recruiting, Iovance Biotherapeutics, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2020 --> Jul 2020
Clinical • Enrollment closed • Trial primary completion date
|
BRAF (B-raf proto-oncogene) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
BRAF mutation • BRAF V600
|
Amtagvi (lifileucel)